Clinical Trial Update: DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial assessing the tolerability of BI 764532 at multiple dose levels when added to standard of care in adults with advanced small cell lung cancer. The…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• BI 764532 (BI 764532)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Small Cell Lung Carcinoma (SCLC) | Phase 1 | Status: ACTIVE_NOT_RECRUITING